Caribou Biosciences (CRBU) to Release Quarterly Earnings on Monday

Caribou Biosciences (NASDAQ:CRBU) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Caribou Biosciences to post earnings of ($0.33) per share and revenue of $1.9570 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 4:00 PM ET.

Caribou Biosciences Stock Down 4.5%

NASDAQ:CRBU opened at $1.90 on Monday. The stock has a market cap of $177.59 million, a PE ratio of -1.12 and a beta of 2.54. The business’s 50-day simple moving average is $1.63 and its two-hundred day simple moving average is $1.91. Caribou Biosciences has a 52 week low of $0.66 and a 52 week high of $3.54.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Citigroup increased their price objective on shares of Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 3rd. HC Wainwright raised their target price on shares of Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. Finally, Truist Financial set a $7.00 target price on Caribou Biosciences in a research note on Tuesday, November 4th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CRBU. Creative Planning acquired a new position in shares of Caribou Biosciences in the 2nd quarter valued at $25,000. Hudson Bay Capital Management LP acquired a new position in shares of Caribou Biosciences during the second quarter worth about $30,000. Russell Investments Group Ltd. increased its position in shares of Caribou Biosciences by 80.0% in the 4th quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock valued at $39,000 after purchasing an additional 10,824 shares during the last quarter. Credit Agricole S A acquired a new stake in Caribou Biosciences in the third quarter valued at $68,000. Finally, US Bancorp DE boosted its holdings in Caribou Biosciences by 18,624.0% in the third quarter. US Bancorp DE now owns 34,265 shares of the company’s stock valued at $80,000 after purchasing an additional 34,082 shares in the last quarter. 77.51% of the stock is owned by hedge funds and other institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.